| __timestamp | ACADIA Pharmaceuticals Inc. | Rhythm Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 32748000 | 1213000 |
| Thursday, January 1, 2015 | 90804000 | 3425000 |
| Friday, January 1, 2016 | 186456000 | 6311000 |
| Sunday, January 1, 2017 | 255062000 | 9518000 |
| Monday, January 1, 2018 | 265758000 | 28080000 |
| Tuesday, January 1, 2019 | 325638000 | 36550000 |
| Wednesday, January 1, 2020 | 388661000 | 46125000 |
| Friday, January 1, 2021 | 396028000 | 68486000 |
| Saturday, January 1, 2022 | 369090000 | 92032000 |
| Sunday, January 1, 2023 | 402466000 | 117532000 |
Data in motion
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, ACADIA Pharmaceuticals has consistently outpaced Rhythm Pharmaceuticals in SG&A spending. From 2014 to 2023, ACADIA's SG&A expenses grew by approximately 1,130%, peaking at $402 million in 2023. In contrast, Rhythm Pharmaceuticals saw a more modest increase of around 9,600%, reaching $118 million in the same year.
Despite ACADIA's higher absolute spending, Rhythm's rapid growth in SG&A expenses reflects its aggressive expansion strategy. However, the challenge remains for both companies to optimize these costs while driving growth. As the pharmaceutical landscape evolves, the ability to manage SG&A expenses effectively will be a key differentiator in achieving long-term success.
SG&A Efficiency Analysis: Comparing Eli Lilly and Company and ACADIA Pharmaceuticals Inc.
AbbVie Inc. and ACADIA Pharmaceuticals Inc.: SG&A Spending Patterns Compared
Vertex Pharmaceuticals Incorporated and ACADIA Pharmaceuticals Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: GSK plc vs ACADIA Pharmaceuticals Inc. Trends and Insights
argenx SE and Rhythm Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Selling, General, and Administrative Costs: Neurocrine Biosciences, Inc. vs ACADIA Pharmaceuticals Inc.
Selling, General, and Administrative Costs: Catalent, Inc. vs Rhythm Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: CymaBay Therapeutics, Inc. vs Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals, Inc. or Amphastar Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Who Optimizes SG&A Costs Better? Rhythm Pharmaceuticals, Inc. or Xencor, Inc.
Breaking Down SG&A Expenses: ACADIA Pharmaceuticals Inc. vs Merus N.V.
Operational Costs Compared: SG&A Analysis of ACADIA Pharmaceuticals Inc. and Ligand Pharmaceuticals Incorporated